Overview
- Medicus said it will present company-reported results from two single-dose Phase 1 studies in 48 healthy premenopausal women at the AACE 2026 meeting.
- The studies showed dose-dependent drops in estradiol, a key ovarian hormone, with some readings in the Barbieri range that aims to ease symptoms while limiting side effects.
- Drug levels followed a depot-like pattern with rapid uptake, a later second peak, and a reported half-life of about 14 to 23 days that could allow fewer injections.
- The company reported no unexpected safety issues and bone turnover markers stayed within normal ranges through Day 29 in these healthy volunteers.
- Medicus plans patient trials for symptomatic endometriosis with Omics Labs in the UAE using biomarker-guided selection, highlighting a gap as no long-acting injectable GnRH antagonists are approved for this condition.